High-dose, short-course levofloxacin for community-acquired Pneumonia: a new treatment paradig

…, AM Tennenberg, MM Khashab… - Clinical infectious …, 2003 - academic.oup.com
Levofloxacin demonstrates concentration-dependent bactericidal activity most closely
related to the pharmacodynamic parameters of the ratio of area under the concentration-time …

Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens

LM Dunbar, MM Khashab, JB Kahn… - … medical research and …, 2004 - Taylor & Francis
Background: Current recommended durations for treatment of atypical community-acquired
pneumonia (CAP) range from 10 to 21 days. However, antibiotics such as the …

Levofloxacin efficacy in the treatment of community-acquired legionellosis

…, RN Greenberg, N Zadeikis, JE Stout, MM Khashab… - Chest, 2004 - Elsevier
Background Although fluoroquinolones possess excellent in vitro activity against Legionella,
few large-scale clinical trials have examined their efficacy in the treatment of Legionnaires …

[HTML][HTML] Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients

AF Shorr, MM Khashab, JX Xiang, AM Tennenberg… - Respiratory …, 2006 - Elsevier
BACKGROUND: The efficacy and safety of 750-mg, 5-day levofloxacin was recently shown
to be comparable to 500-mg, 10-day levofloxacin in a randomized, double-blind, multicentre …

Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia

…, AM Tennenberg, JX Xiang, MM Khashab… - … medical research and …, 2004 - Taylor & Francis
Objective: To evaluate the time to symptom resolution and IV-to-PO transition in community-acquired
pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. Research …

Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections

MM Khashab, J Xiang, JB Kahn - Current medical research and …, 2006 - Taylor & Francis
Objective: To compare safety data with levofloxacin 500 mg and 750 mg from clinical trials
for the treatment of respiratory infections. Methods: We compared adverse event data for …

[HTML][HTML] Percutaneous hydrodiscectomy surgery effectiveness in chronic back pain (hydrodiscectomy in chronic back pain)

MA Khashab, MA Elkhalifa, HO Hafiz… - Neurosciences …, 2023 - nsj.org.sa
Objectives: To investigate the pre-operative and post-operative characteristics of patients
suffering from chronic back and radicular pain who had percutaneous hydrodiscectomy. …

Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis …

RF Grossman, ME Ambrusz, AC Fisher, MM Khashab… - Clinical …, 2006 - Elsevier
This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel,
noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of …

[HTML][HTML] Open versus Minimally invasive transforaminal lumbar interbody fusion: Intermediate outcomes in overweight and obese patients

MA Khashab, MM Alswat, BS Alsofiani… - Journal of …, 2020 - journalmsr.com
Objectives: To compare the intermediate results between minimally invasive transforaminal
lumbar interbody fusion (MIS-TLIF) and open approach in obese and overweight patients. …

[HTML][HTML] Effectiveness and outcome of spinal decompression surgery in overweight and obese patients

MA Khashab, M Elkhalifa - Journal of Musculoskeletal Surgery …, 2022 - journalmsr.com
Objectives: Minimal invasive spinal surgery (MISS) is a relatively new surgical approach that
minimizes tissue damage, reduces blood loss, and promises faster post-operative recovery …